Dermatology and therapy · 2026
Effectiveness and Tolerability of Low-Dose Micronized Isotretinoin in Patients with Severe Recalcitrant Nodular Facial Acne in India: a Real-World Retrospective Study Using Electronic Medical Records.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chandrashekar Byalakere S, Vedamurthy Maya, Kolalapudi Seetharamanjaneyulu, Mallela Vijaya Bhaskar, Arsiwala Shahnaz, Ganjoo Anil, Saraswat Abir, Modi Farida, Sujatha Sowmya C, Udare Satish, Gorai Surajit, Gabhane Mukesh, Lalan Bhavesh, Jani Gaurang, Jain Aditi, Dharmadhikari Shruti, Khandhedia Chintan, Devkare Prashant, Mane Amey, Shaikh Asif, Mehta Suyog
Аннотация
INTRODUCTION: Severe recalcitrant nodular facial acne is a chronic inflammation with considerable psychosocial impact. Conventional oral isotretinoin is effective, but optimal absorption necessitates dietary compliance. Micronized formulations improve bioavailability and allow flexible dosing. This study evaluated the effectiveness and tolerability of low-dose micronized isotretinoin.
METHODS: This real-world, retrospective, multicenter, observational study analyzed aggregated and anonymized electronic medical records (EMRs) collected over approximately 12 months from patients aged ≥ 12 years with severe recalcitrant nodular facial acne who were treated with low-dose micronized isotretinoin for ≥ 8 weeks. The primary endpoint was improvement in acne severity [in terms of Investigator's Global Assessment (IGA) score] from baseline to 8 ± 2 weeks. Secondary endpoints included improvement at the end of treatment, investigator-graded response, and incidence of adverse events (AEs; serious AEs [SAEs]). Exploratory endpoints assessed patient-graded response and change in nodular/total lesion count.
RESULTS: Among 305 patients (86.89% adults; 13.11% adolescents), 59.67% had an IGA score of 3 and 40.33% had an IGA score of 4 at baseline. Post-treatment, the overall IGA score reduced significantly from 3.40 ± 0.49 at baseline to 2.11 ± 0.79 at 8 ± 2 weeks (37.94% reduction; p < 0.001), 1.30 ± 0.82 at 12 ± 2 weeks (61.76% reduction; p < 0.001), and 0.53 ± 0.73 at 16 ± 2 weeks (84.41% reduction; p < 0.001). By 16 ± 2 weeks, 91.81% patients were graded 'clear'/'almost clear' (IGA score ≤ 1), 67.87% had 'excellent' investigator-graded response, and 65.25% had 'very good' self-graded response. After 16 ± 2 weeks, significant reductions were observed in nodular lesion counts (from 7.06 ± 9.22 to 0.38 ± 1.29; 94.62% reduction; p < 0.001) and total lesions (from 32.25 ± 36.95 to 2.46 ± 4.63; 92.37% reduction; p < 0.001). Six (1.97%) patients experienced AEs; no SAE was observed.
CONCLUSION: In this real-world EMR-based study, low-dose micronized isotretinoin was found to be clinically effective and well tolerated in patients with severe recalcitrant nodular facial acne, achieving rapid and sustained improvements in lesion counts and acne severity.
TRIAL REGISTRATION: Clinical Trials Registry-India, identifier CTRI/2024/07/070813.
METHODS: This real-world, retrospective, multicenter, observational study analyzed aggregated and anonymized electronic medical records (EMRs) collected over approximately 12 months from patients aged ≥ 12 years with severe recalcitrant nodular facial acne who were treated with low-dose micronized isotretinoin for ≥ 8 weeks. The primary endpoint was improvement in acne severity [in terms of Investigator's Global Assessment (IGA) score] from baseline to 8 ± 2 weeks. Secondary endpoints included improvement at the end of treatment, investigator-graded response, and incidence of adverse events (AEs; serious AEs [SAEs]). Exploratory endpoints assessed patient-graded response and change in nodular/total lesion count.
RESULTS: Among 305 patients (86.89% adults; 13.11% adolescents), 59.67% had an IGA score of 3 and 40.33% had an IGA score of 4 at baseline. Post-treatment, the overall IGA score reduced significantly from 3.40 ± 0.49 at baseline to 2.11 ± 0.79 at 8 ± 2 weeks (37.94% reduction; p < 0.001), 1.30 ± 0.82 at 12 ± 2 weeks (61.76% reduction; p < 0.001), and 0.53 ± 0.73 at 16 ± 2 weeks (84.41% reduction; p < 0.001). By 16 ± 2 weeks, 91.81% patients were graded 'clear'/'almost clear' (IGA score ≤ 1), 67.87% had 'excellent' investigator-graded response, and 65.25% had 'very good' self-graded response. After 16 ± 2 weeks, significant reductions were observed in nodular lesion counts (from 7.06 ± 9.22 to 0.38 ± 1.29; 94.62% reduction; p < 0.001) and total lesions (from 32.25 ± 36.95 to 2.46 ± 4.63; 92.37% reduction; p < 0.001). Six (1.97%) patients experienced AEs; no SAE was observed.
CONCLUSION: In this real-world EMR-based study, low-dose micronized isotretinoin was found to be clinically effective and well tolerated in patients with severe recalcitrant nodular facial acne, achieving rapid and sustained improvements in lesion counts and acne severity.
TRIAL REGISTRATION: Clinical Trials Registry-India, identifier CTRI/2024/07/070813.